Stonepine Capital Management LLC Boosts Stock Holdings in Enanta Pharmaceuticals, Inc. $ENTA

Key Points

• Stonepine Capital Management LLC increased its stake in Enanta Pharmaceuticals by 78.0%, acquiring a total of 590,742 shares, which constitutes around 3.1% of its overall portfolio.
• Enanta Pharmaceuticals reported a loss of ($0.85) earnings per share for the last quarter, surpassing analyst expectations, and had revenue of $18.31 million, exceeding the consensus estimate.
• The stock has a consensus buy rating from analysts, with a price target of $21.67, while its shares currently trade at approximately $8.83.

Stonepine Capital Management LLC grew its stake in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA - Free Report) by 78.0% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 590,742 shares of the biotechnology company's stock after buying an additional 258,842 shares during the quarter. Enanta Pharmaceuticals accounts for 3.1% of Stonepine Capital Management LLC's investment portfolio, making the stock its 9th biggest position. Stonepine Capital Management LLC owned 2.77% of Enanta Pharmaceuticals worth $3,261,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. US Bancorp DE purchased a new stake in shares of Enanta Pharmaceuticals during the 1st quarter valued at $36,000. Tower Research Capital LLC TRC raised its position in Enanta Pharmaceuticals by 46.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 7,202 shares of the biotechnology company's stock worth $41,000 after purchasing an additional 2,274 shares during the period. GAMMA Investing LLC purchased a new position in Enanta Pharmaceuticals in the 1st quarter worth $40,000. Squarepoint Ops LLC purchased a new position in Enanta Pharmaceuticals in the 4th quarter worth $66,000. Finally, Velan Capital Investment Management LP purchased a new position in Enanta Pharmaceuticals in the 4th quarter worth $75,000. Hedge funds and other institutional investors own 94.99% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have issued reports on the stock. JMP Securities boosted their price objective on shares of Enanta Pharmaceuticals from $24.00 to $25.00 and gave the company a "market outperform" rating in a research report on Tuesday, August 12th. HC Wainwright assumed coverage on shares of Enanta Pharmaceuticals in a research report on Monday, July 28th. They issued a "buy" rating and a $20.00 price objective on the stock. Finally, Wall Street Zen upgraded shares of Enanta Pharmaceuticals from a "sell" rating to a "hold" rating in a research report on Sunday, June 22nd. Three research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and an average target price of $21.67.

Enanta Pharmaceuticals Stock Down 0.1%

Shares of ENTA traded down $0.01 during trading hours on Tuesday, reaching $8.65. 89,379 shares of the company traded hands, compared to its average volume of 166,118. The company's fifty day moving average price is $7.55 and its two-hundred day moving average price is $6.67. The company has a market capitalization of $184.94 million, a price-to-earnings ratio of -2.00 and a beta of 0.88. Enanta Pharmaceuticals, Inc. has a 12 month low of $4.09 and a 12 month high of $13.43.

Enanta Pharmaceuticals (NASDAQ:ENTA - Get Free Report) last announced its earnings results on Monday, August 11th. The biotechnology company reported ($0.85) earnings per share for the quarter, beating analysts' consensus estimates of ($1.25) by $0.40. The firm had revenue of $18.31 million for the quarter, compared to analyst estimates of $16.21 million. Enanta Pharmaceuticals had a negative net margin of 141.98% and a negative return on equity of 89.02%. On average, analysts expect that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.